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Abstract
Background: Facial volume loss contributes significantly to facial aging. The 20-mg/mL hyaluronic
acid (HA) formulation used in this study is a smooth, highly cohesive, viscous, fully reversible,
volumizing filler indicated to restore facial volume. This first prospective study evaluated use in
current aesthetic clinical practice.
Methods: A pan-European evaluation conducted under guidelines of the World Association of
Opinion and Marketing Research, the trial comprised a baseline visit (visit 1) and a follow-up (visit
2) at 14 ± 7 days posttreatment. Physicians photographed patients at each visit. Each patient was
treated with the 20-mg/mL HA volumizing filler as supplied in standard packaging. Procedural
details, aesthetic outcomes, safety, and physician and patient ratings of their experience were
recorded.
Results: Fifteen physicians and 70 patients (91% female; mean age: 50 years) participated. Mean
volume loss at baseline was 3.7 (moderate) on the Facial Volume Loss Scale. Local anesthesia was
used in 64.3% of cases. Most injections (85%) were administered with needles rather than cannulas.
Of the 208 injections, 59% were in the malar region, primarily above the periosteum. Subcutaneous
injections were most common for other sites. The mean total injection volume per patient was 4.6
mL. The mean volume loss score declined significantly (P < .001) to 2.1 at visit 2. On the Global
Aesthetic Improvement Scale, 88% and 76% of the treatments were rated very much improved or
much improved by physicians and patients, respectively. Of the physicians, 95.6% rated this HA filler
as very or fairly easy to use. Similarly, 92% of patients were very likely or quite likely to return for
treatment; nearly all (98%) would recommend this treatment to friends. Transient (mean duration:
5.5 days) injection-site adverse events (AEs) occurred in 24 patients. Bruising was the most
common AE.
Conclusion: The 20-mg/mL smooth, highly cohesive, viscous, volumizing HA filler was effective,
well tolerated, and easy to use in current clinical practice. Participants were very likely to
recommend this product to colleagues and friends, and patients would be very or quite likely to
request this product for future treatments.
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Background
Facial aging is a consequence of multiple, interacting
intrinsic and extrinsic factors.[1] Sun exposure, or photo-
aging, contributes importantly to the intrinsic changes
associated with aging. These changes have been described
using the Glogau photoaging classification, which focuses
on the degree of wrinkling.[2] Another factor in the
appearance of facial aging is the lifelong activity of the
muscles of facial expression, which produce the dynamic
and, ultimately, static facial lines and folds.[3] It has also
long been recognized that gravity exerts a toll on the facial
structures as tissue loses its elasticity and becomes less
able to resist stretching.
Volume deficits resulting from the loss and repositioning
of facial fat, as well as from skeletal remodeling, are now
increasingly appreciated as a fundamental component of
facial aging.[1,4,5] The younger face is characterized by
the harmony and balance captured in the classic heart
shape or inverted triangle.[1,6] The reversal of this "trian-
gle of beauty" as aging proceeds and as proportions rear-
range is considered generally less aesthetically appealing.
With these changes, the convexities typical of a youthful
appearance tend to flatten and droop.
Recognition of the key role of volume loss in facial aging
has resulted in what has been called a paradigm shift in
facial rejuvenation, influencing both the types and extent
of surgical procedures, as well as the way in which mini-
mally invasive approaches are employed.[7] Facial rejuve-
nation has moved beyond wrinkle effacement and
surgical facelifts to an approach that relaxes muscles and
volumizes, shapes, recontours, and retexturizes. In combi-
nation with preventive skin care measures, this compre-
hensive, multimodal approach permits clinicians to
develop aesthetic treatment plans tailored to individual
patient needs and designed to produce a natural, relaxed
appearance.[6,8]
Subdermal fillers can form a cornerstone of the new facial
rejuvenation paradigm. The product that was the subject
of this study, a 20-mg/mL smooth, highly cohesive, vis-
cous HA volumizing filler, shares many of the properties
of its wider family of 24-mg/mL smooth, cohesive HA fill-
ers, but also has unique physical and chemical properties
that make it ideally suited for volumizing and contouring.
These products are smooth, cohesive HA fillers as a result
of the manufacturing process in which they are homoge-
nized rather than sieved to produce the final product.[9]
This is in comparison with hard and granular formula-
tions produced by the sieving process. [9,10] The 20-mg/
mL smooth, cohesive HA filler was designed to be more
viscous and robust with a higher lift capacity than other
members of its family. The 20-mg/mL smooth, cohesive
HA filler is derived primarily from low-molecular-weight
(LMW) HA. Its HA concentration, 20 mg/mL, and its
water binding capacity is similar to that of other 24-mg/
mL smooth, cohesive products. Crosslinking of LMW HA
results in significantly increased viscosity. As a result, the
final product has very high viscosity and cohesivity while
remaining soft and readily extrudable. It also retains the
properties of reversibility, in the event of overcorrection or
complications, and resorbability. At the same time, the
product has the potential for long-term persistence in tis-
sue.
The 20-mg/mL smooth, highly cohesive, viscous HA volu-
mizing filler has been evaluated retrospectively in patients
with age-related volume loss and prospectively in patients
with human immunodeficiency virus (HIV)-associated
lipoatrophy.[1,11] The results of both of these studies
demonstrated that the 20-mg/mL smooth, cohesive HA
volumizing filler was highly effective and well tolerated.
Aesthetic improvements were also durable, with reported
longevities of at least 12 and up to 18 months based on
the defined durations of each study.[1,11]
In this article, we report on the first prospective trial
designed to assess how the 20-mg/mL smooth, cohesive
HA volumizing filler is used in current clinical practice.
Specific objectives were to characterize the aesthetic bene-
fit and safety profile of the 20-mg/mL smooth, cohesive
HA volumizing filler; to evaluate patient and clinician per-
spectives on the product; to assess practice preferences,
including similarities, and differences among specialties;
and to derive practice recommendations.
Methods
Study Design
This was a prospective, open-label, nonrandomized study
in which a 20-mg/mL smooth, highly cohesive, viscous
HA volumizing filler (Juvéderm™ VOLUMA™, Allergan,
Pringy, France) was evaluated within its indicated use of
restoring facial volume. The study was funded by Allergan,
Inc. This Europe-wide evaluation was conducted under
the guidelines of the World Association of Opinion and
Marketing Research (ESOMAR) to evaluate current usage
of the 20-mg/mL smooth, cohesive HA volumizing filler
in European countries in which the product is CE-marked
or licensed and available. Evaluations took place within
standard practice procedures without the inclusion of any
additional monitoring or diagnostic procedures. The con-
duct of the trial complied with the provisions of the Hel-
sinki Declaration for studies in humans; however, it was
not a clinical trial as such. As a market research evaluation
of a CE-marked device within intended use, regulatory
approval is not required, and therefore, ethics approval
was not sought.
Patients
Men and women of at least 30 years of age who requested
treatment for facial volume loss and who were able to pro-BMC Dermatology 2009, 9:9 http://www.biomedcentral.com/1471-5945/9/9
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vide informed consent were eligible for participation.
They were required to have a facial volume loss score of at
least 2 on the 5-point Facial Volume Loss Scale.[12] Pro-
spective patients were excluded if they were participants in
any ongoing clinical trial or had any conditions contrain-
dicating the use of the 20-mg/mL smooth, cohesive HA
volumizing filler, such as a tendency to develop hyper-
trophic scars, known hypersensitivity to HA, or pregnancy
or lactation.[13] The presence of inflamed or infected skin
(eg, acne, herpes) in the planned treatment areas pre-
cluded participation. Also excluded were patients who
had received any previous treatment with a permanent or
semipermanent filler or implant within the preceding 12
months.
Study Procedures
The study comprised 2 visits. Visit 1 was the injection day,
which took place on day 1. Visit 2 was the follow-up,
which took place at day 14 (± 7 days) (Figure 1). Case
assessment forms were completed by each investigator at
each visit and served as the basis for data collection. This
included details on the clinical practice and physician spe-
cialty, patient age and sex, and all outcome variables. Pre-
and posttreatment digital photography of frontal, lateral,
and oblique views were taken at both visits. Patients com-
pleted a questionnaire at the second visit to rate their per-
ceptions of their experience.
Investigators injected the 20-mg/mL smooth, cohesive HA
volumizing filler with either a cannula or needle, accord-
ing to their usual practices. They determined the volume
to be injected based on patient assessment using the Facial
Volume Loss Scale (1 = mild, 2 = intermediate between
mild and moderate, 3 = moderate, 4 = intermediate
between moderate and severe, 5 = severe) and their aes-
thetic judgment. Touch-ups could be performed at visit 2
based on the judgment of the investigator. The use of
anesthetic also depended upon the preferences and usual
practice of the treating physician.
Data Collection and Study Endpoints
Investigators recorded each patient's age, sex, and baseline
volume loss according to the Facial Volume Loss Scale. At
the time of treatment, investigators recorded the type(s) of
anesthesia, the type and size of the injection device (nee-
dle or cannula), the injection sites and volume per site,
the total volume, and the injection plane and pattern.
They also assessed the ease of injection, sculpting, and
shaping with the 20-mg/mL smooth, cohesive HA volu-
mizing filler, and recorded their posttreatment instruc-
tions for patients.
Effectiveness was assessed at visit 2 and was based on
investigator-assessed changes from baseline on the Facial
Volume Loss Scale and on investigator and patient ratings
on the Global Aesthetic Improvement Scale (GAIS),
which includes 5 categories ranging from very much
improved to worse.[14] The need for touch-ups was eval-
uated. This included the reason, the site, the injection
technique and plane, and the volume. Safety was moni-
tored by recording the occurrence of any adverse event
(AE) that followed treatment, including its site, severity,
and duration. Severity was determined by the usual clini-
cal criteria of each individual investigator. At this visit,
investigators also noted their willingness to recommend
the 20-mg/mL smooth, cohesive HA volumizing filler to
their colleagues.
At visit 2, patients completed their questionnaire, record-
ing their satisfaction with the overall cosmetic effect, their
likelihood of returning for additional treatments with the
20-mg/mL smooth, cohesive HA volumizing filler, and
their willingness to recommend it to their friends.
Data Analyses
The data were summarized with descriptive statistics (eg,
percentages, means, ranges). The differences between pre-
treatment and posttreatment mean Facial Volume Loss
Scale scores were analyzed using a t-test.
Results
Study Participants
Fifteen physicians (from France, Germany, Italy, Spain,
the United Kingdom, Benelux countries, and Russia
[licensed as Voluma Corneal® in Russia]) participated in
the study. Of these, 4 were dermatologists, 6 plastic sur-
geons, and 5 aesthetic practitioners. A total of 70 patients
were recruited. The majority were female with a mean age
of 50 years (Table 1). Based on the Facial Volume Loss
Scale mean score (3.7), patients on average had a some-
what greater than moderate loss of facial volume. Mean
ratings by specialty were 3.7, 4.0, and 3.2 for dermatolo-
Study flow and treatment Figure 1
Study flow and treatment.
Day 1
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Day 14 (±7)
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gists, plastic surgeons, and aesthetic practitioners, respec-
tively.
Treatment and Practice Characteristics
The type of anesthesia used was recorded for 56 of the 70
patients. Across all physicians, local anesthesia was used
in the majority (64.3%) of the 56 patients (Table 2). Some
differences among specialties were apparent. For example,
topical anesthetics were used for 44% of treatments by
dermatologists and for 27% by plastic surgeons. In con-
trast, aesthetic practitioners used local anesthesia for 95%
of their treatments.
Needles were used to deliver product for 85% of all injec-
tions (Table 3). The median needle gauge was 21 (range:
21–27 gauge).(Excel spreadsheet, Column L [Q5CA]) The
median cannula size was 18 gauge (range: 11.6–19 gauge)
(Excel spreadsheet column M [Q5DA])
The most frequent treatment site for each side of the face
was the malar area, accounting for 59% of the 208 total
injections (Table 4). The mean injection volume in the
malar region was 1.9 mL/side. The next most commonly
injected site (21% of procedures) was the nasolabial fold
area with a mean injection volume of 1.45 mL/side.
Across all patients and all areas, the mean total volume
per patient was 4.6 mL. Dermatologists and plastic sur-
geons injected greater total volumes per patient than did
aesthetic practitioners. The mean total volume injected
per patient by dermatologists was 5.5 mL, by plastic sur-
geons was 5.4 mL, and by aesthetic practitioners was 3.0
mL.
All injections were in the deep dermis or above the perios-
teum as recommended in the product instructions for
use.[13] In the malar area, the majority of injections were
subcutaneous (39%) or above the periosteum (40%). In
other areas, subcutaneous injections predominated. Lin-
ear threading was the most common injection technique
for the malar area (36%), chin (59%), and nasolabial
folds (51%). Fanning was the most common technique
used for the temporal area (58%) and other areas (57%.)
Some differences among specialties were noted. Derma-
tologists used cross-hatching 47% of the time, linear
threading 28% of the time, and a combination of tech-
niques 40% of the time. Plastic surgeons used linear
threading 37% of the time, followed by fanning (24%),
cross-hatching (16%), and combinations (18%). Aes-
thetic practitioners used primarily cross-hatching (48%),
then fanning (22%), and combinations (16%).
Aesthetic Outcomes
Effectiveness
The mean scores on the Facial Volume Loss Scale declined
significantly (P < .001) from 3.7 at visit 1 to 2.1 at Visit 2.
The change in score distributions demonstrates that 78%
of patients had been rated as a having a medium degree of
volume loss pretreatment compared with 29% posttreat-
ment (Figure 2). At visit 2, 70% of patients were rated as
having a low degree of volume loss.
Investigators rated improvement on the GAIS for 68
patients; 88% were rated as very much or much improved,
and the remaining patients (12%) were rated as improved
(Figure 3). Of the 70 patients, 76% rated themselves as
very much or much improved (Figure 3). Only one
patient noted no change in appearance. Thus 99% of the
patients rated themselves as improved. Figure 4 illustrates
changes in appearance of a typical patient.
Table 1: Patient Baseline and Demographic Data (N = 70)
Characteristic Value
Sex 91% female
Mean age 50
Ascher Scale (mean score) 3.7
Ascher Scale (score distributions)* Grade 2: 44%
Grade 3: 34%
Grade 4: 14%
Grade 5: 3%
*Total does not equal 100 because 3 patients did not meet the 
enrollment criterion of a volume loss score of at least 2 at baseline.
Table 2: Type of Anesthesia
Anesthesia (n = 56)
Local Topical Both Regional or Block
64.3% 19.6% 1.8% 14.3%
Table 3: Type of Injection Device
Device
178 Mentions
Needle Cannula
85% 15%
Table 4: Injection Sites and Volumes*
Injection Sites (Mean Volume/Side)
208 Sites Recorded
Malar Nasolabial Folds Chin Temporal Other
59%
(1.9 mL)
21%
(1.45 mL)
9%
(0.5 mL)
7%
(0.7 mL)
5%
(1.75 mL)
*Total exceeds 100% because of rounding.BMC Dermatology 2009, 9:9 http://www.biomedcentral.com/1471-5945/9/9
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Touch-Ups
Nine patients (13%) were deemed to require touch-ups.
The most common reason was the need for additional
volume. Two touch-ups were needed to correct an uneven
result. For the right side, 8 patients were treated with an
additional mean volume of 0.8 mL. Five patients required
an additional mean volume of 0.7 mL on the left side. The
total mean additional volume added at visit 2 was 1.5 mL.
Posttreatment recommendations
Specific posttreatment recommendations varied consider-
ably across participating physicians but were generally
consistent with typical practice for any facial filler. The
more commonly mentioned recommendations to
patients were to avoid massaging the area for at least 24
hours, sauna treatments, vigorous sports, sleeping face-
down, and anticoagulant medications such as aspirin.
Volume loss ratings on the Ascher Scale[12]: changes from baseline to follow-up Figure 2
Volume loss ratings on the Ascher Scale[12]: changes from baseline to follow-up.
At Baseline
(n=70)
High
(Grades 4 and 5)
Patients Patients
Grade 5 3%
Medium
(Grades 2 and 3)
Low
(Grade 1 and 
Normal)
At Follow-Up
(n=66)
Grade 4 14%
Grade 3 34%
Patients with low facial volume
loss were not eligible to 
participate in the pilot
Grade 2 44%
Grade 1 3%
Normal 1%
0% 20% 40% 60%
Grade 5
Grade 4 2%
Grade 3 5%
Grade 2 24%
Grade 1 46%
Normal 24%
0% 20% 40% 60%
Mean score 3.7 (Pre) to 2.1 (Post) P<.001
Physician and patient ratings on the Global Aesthetic Improvement Scale Figure 3
Physician and patient ratings on the Global Aesthetic Improvement Scale.
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Patients were also cautioned to expect the possibility of
bruising and swelling.
Safety
The majority (66%) of the 70 patients experienced no
AEs. A total of 24 patients experienced injection-site reac-
tions (Table 5). The mean duration of these events was 5.5
days (range: 2–15 days). Seven of the AEs were rated as
severe (bruising and swelling, n = 2; pain and swelling, n
= 2, pain, n = 1; infection and swelling, n = 1, pain and
bruising, n = 1).
For the patient who experienced posttreatment infection,
previous aesthetic treatments included onabotulinumtox-
intypeA (BOTOX®), synthetic polyacrylamide gel polymer
filler (Bio-Alcamid™; Rofil), and lip augmentation with
synthetic polyacrylamide gel polymer filler (Beautical 2®;
Rofil). Prior polyacrylamide treatments were not dis-
closed to the treating physician. Four months after injec-
tion with 2 mL of the 20-mg/mL smooth, highly cohesive,
viscous HA volumizing filler into the malar area and chin;
a biofilm and abscess developed. The event was deter-
mined to be unrelated to treatment with the 20-mg/mL
smooth, highly cohesive, viscous HA volumizing filler.
The patient was treated with amoxicillin/clavulanic potas-
sium (Augmentin®) 3 times daily for 10 days, and with
ibuprofen 600 mg, 3 times daily for 7 days. The site was
evacuated and cleansed, and the symptoms fully resolved
without further sequelae.
Physician Experience and Perspectives on Treatment
When asked to rate ease of use, approximately 95.6% of
investigators rated the 20-mg/mL smooth, cohesive HA
volumizing filler as very or fairly easy to inject, regardless
of injection technique or plane (Figure 5). Similarly, 96%
of investigators rated the product as very or fairly easy to
sculpt or shape in the majority of patients. Physicians
were asked to note whether they would recommend the
20-mg/mL smooth, cohesive HA volumizing filler to col-
leagues after each treatment they completed. Data were
available for 67 treatment sessions, of which 98% were
positive.
Patient Experience and Perspectives
Patient experience with the 20-mg/mL smooth, cohesive
HA volumizing filler was highly positive, with 98% of
patients reporting that they would recommend the treat-
ment to their friends (Figure 6). Approximately 92% of
the patients noted that they would be quite likely or very
likely to return for treatment (Figure 6).
Discussion
To our knowledge, this was the first prospective evalua-
tion on the use of a 20-mg/mL smooth, highly cohesive,
viscous HA volumizing filler in current aesthetic clinical
practice. The study was designed to characterize treatment
techniques, assess effectiveness and safety, and evaluate
physician and patient perspectives on the experience.
Patients with facial volume loss of at least 2 on the Facial
Volume Loss Scale were eligible. A total of 70 patients and
15 investigators (dermatologists, plastic surgeons, and
aesthetic practitioners) participated.
Most injections were performed under local anesthesia
and needles were used in the majority of treatments,
although both needles and cannulas will be available in
the supplied standard product package. The most com-
mon treatment area was the malar region with a mean
Typical patient treated with the 20-mg/mL smooth, cohesive  HA volumizing filler Figure 4
Typical patient treated with the 20-mg/mL smooth, 
cohesive HA volumizing filler. This 37-year-old patient 
with volume loss of grade 3 on Ascher Scale was injected in 
each malar region of her face with 2 mL of the 20-mg/mL 
smooth, cohesive HA volumizing filler. The injections were 
made above the periosteum using the linear threading tech-
nique. Written consent for publication was obtained from 
the patient.
Table 5: Adverse Events
Event Number of Patients (n = 24)
Bruising 7
Pain and bruising 4
Swelling 3
Bruising and swelling 3
Pain and swelling 2
Pain 2
Bruising and bleeding 1
Infection and swelling 1
Not specified 1BMC Dermatology 2009, 9:9 http://www.biomedcentral.com/1471-5945/9/9
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Physician ratings: ease of use and sculpting Figure 5
Physician ratings: ease of use and sculpting.
Difficult 
Ease of Sculpting  Ease of Injection 
Very easy
Fairly easy
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Not easy
0%
10%
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30%
40%
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54.4%
4.4%
0% 0%
35.3%
60.3%
4.4%
0% 0%
Patient ratings Figure 6
Patient ratings. Percentage of patients who would recommend the 20-mg/mL smooth, cohesive HA volumizing filler to 
friends. Likelihood of returning for additional treatment with the 20-mg/mL smooth, cohesive HA volumizing filler.
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total injection volume per patient of 4.6 mL. Regardless of
technique, treatment area, or specialty, the vast majority
of physicians found the 20-mg/mL smooth, cohesive HA
volumizing filler to be easy to inject, sculpt, and mold.
Treatment with the 20-mg/mL smooth, highly cohesive,
viscous HA volumizing filler resulted in statistically signif-
icant improvements in facial volume. Indeed, 70% of
patients were rated as having a low degree of volume loss
posttreatment, a substantial change from pretreatment.
The vast majority of patients and physicians rated the
changes in appearance as much or very improved, and the
majority of patients did not experience any AEs. Based on
patient ratings, including their high likelihood of return-
ing for treatment and of recommending it for friends, the
outcomes provided a high degree of patient satisfaction,
one of the most important outcomes in aesthetic medi-
cine. The results from this study are consistent with those
of the first retrospective analysis of the 20-mg/mL
smooth, highly cohesive, viscous HA volumizing filler
(Juvéderm™ VOLUMA™) in a case series of 102 patients
with age-related facial volume loss.[1] This retrospective
study, however, differed from the current study in the vol-
ume loss scale that was used, and that patients were eval-
uated at 30 days after treatment to allow all potential
treatment site responses to fully subside. Data from other
published studies also reveal that the 20-mg/mL smooth,
highly cohesive, viscous HA volumizing filler provides a
durable response of at least 12 to 18 months when used
for restoring facial volume lost through aging or resulting
from HIV-associated lipoatrophy.[1,11] It is very impor-
tant to note that there were no instances of migration or
mobility of the product, nor any irregularities in appear-
ance in the injection area. In contrast, clinical experience
with the 20-mg/mL 1,000 particle, granular consistency
HA filler (Restylane® SubQ) has revealed migration from
the injection area, which is speculated to be the result of
its low cohesivity and nonhomogenous formulation.
Together, the properties of the 20-mg/mL smooth, highly
cohesive, viscous HA volumizing filler render it highly
suitable for use in the malar and chin areas. Note that in
this study, very experienced investigators used the product
for deep injections into the nasolabial folds, but it is not
indicated or recommended for routine use in either this
area or in the lips, as they require more superficial treat-
ment. Other products, like the 24-mg/mL smooth, cohe-
sive HA filler and other HAs are more suitable for use in
these areas. Caution is also warranted when injecting
additional fillers in patients who have previously been
treated with synthetic polyacrylamide gel polymer fillers.
Volumizing procedures require somewhat greater skill
than more superficial dermal filling procedures; specifi-
cally, that injections should be placed into the deep der-
mis or above the periosteum, and should be placed under
the orbicularis oculi, but strictly above the deep zygomat-
icus. The temporal branch of the facial nerve should be
avoided. Likewise, it is important to educate patients
about the differences between volumizing procedures and
dermal filling. Patients should be advised that swelling
may occur and is not unusual. Nevertheless, 66% of the
patients experienced no AEs. Observed AEs were consist-
ent with those expected when volumizing the face and
were primarily local (bruising and pain) and self-limited
with a mean duration of 5.5 days.
The variations we observed in techniques, including use
and type of anesthesia, needle versus cannula, planes of
injection, and in injection techniques (eg, linear thread-
ing, cross-hatching, fanning) suggest that the product can
be used successfully according to the individual physi-
cian's or surgeon's preference. There are advantages and
limitations to both cannulas and needles, both of which
are supplied with the product. For example, needle use
may be easier than the cannula and may offer greater pre-
cision. Tissue trauma, however, and the risk of hematoma
may be greater with multiple needle injection sites. It
should be noted that these risks can be reduced by using a
needle and administering only 1 or 2 injections.[1] The
cannula technique may result in less bleeding, but it looks
more aggressive. This must be balanced against the poten-
tial for a lower degree of precision. In this study, very few
patients required touch-ups when evaluated approxi-
mately 2 weeks posttreatment. In actual practice, we rec-
ommend evaluating for touch-ups at 1 month
posttreatment to be sure that all edema, however mini-
mal, have completely resolved and HA water absorption is
complete.
Conclusion
This 20-mg/mL smooth, highly cohesive, viscous, fully
reversible, resorbable, HA volumizing filler is indicated
for restoring facial volume loss.[13] In practice this may
result from aging, congenital anatomic defects, or HIV-
associated lipoatrophy.[1,11] As shown in this study, the
physical and chemical properties of the 20-mg/mL
smooth, cohesive, HA volumizing filler make it robust
and ideal for volumizing, yet still easy to inject, mold, and
sculpt. It should be emphasized that volumizing is not a
procedure to be undertaken without thorough knowledge
of facial anatomy and physiology nor without proper
training because it differs from the more superficial proce-
dures with fillers. The results of this prospective evalua-
tion of actual clinical practice demonstrate that the 20-
mg/mL smooth, cohesive, HA volumizing filler provides a
very effective, well-tolerated approach to volumizing an
aging face. Participants did not report any occurrences of
product migration, which differs from reported clinical
experience with the 20-mg/mL 1,000 particle, granular
consistency HA filler. The 20-mg/mL smooth, highly
cohesive, viscous HA volumizing filler provided a high
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